Меню
Набор скоро начнётся NCT06661343

Pre-exposure Prophylaxis (PrEP) Adherence for Black MSM

Без фазы С лечением HIV Prevention

Ориентир для пациента и семьи

Простыми словами

Автоматическая сводка по структурированным данным реестра. Она помогает сориентироваться, но не заменяет официальный протокол или оценку врача.

Что изучают
В протоколе указаны: C4 Program, C4 + 3MV Program.
Кому может быть актуально
Состояния в реестре: HIV Prevention. Базовые параметры: от 18 лет · Мужчины.
Что важно проверить
Возраст, диагноз и пол — только базовые ориентиры. Предыдущее лечение, анализы и другие обязательные условия указаны ниже в критериях участия.
Где проводится
США
Следующий шаг
Сохраните исследование, покажите его лечащему врачу и уточните актуальный статус у исследовательского центра. Расходы, документы и поездка →
Официальное название

A Multi-Level Integrated Strategy to Optimize PrEP Adherence for Black MSM and Accelerate Implementation at Scale

Обзор

The goal of this clinical trial is to learn if two interventions-C4 and C4+3MV-can improve PrEP adherence (taking medication to prevent HIV) among Black men who have sex with men (MSM). The study will also explore the most effective ways to support participants in continuing their PrEP use over time. The main questions it aims to answer are: * Does the C4 program help participants take PrEP more regularly? * Does adding the 3MV intervention to C4 provide additional support for adherence? Researchers will compare two intervention strategies to see if they result in better PrEP adherence: * C4 Intervention: A program focused on individualized care coordination and addressing structural needs. * C4 + 3MV Intervention: A combination of care coordination with additional behavioral change sessions. Participants will: * Participate in PrEP education and counseling sessions. * Have their PrEP use monitored through dried blood spot (DBS) tests. * Complete questionnaires about their experiences and challenges with PrEP. Receive support sessions tailored to address individual barriers to PrEP adherence.

Подробное описание

This clinical trial aims to evaluate two intervention strategies-C4 and C4 + 3MV-to improve adherence to PrEP (pre-exposure prophylaxis) among Black men who have sex with men (MSM) in two metropolitan areas: Dallas/Fort Worth and New York City. The study addresses structural and behavioral barriers to PrEP adherence, aiming to reduce disparities in HIV prevention efforts.

Study Design and Methodology:

* Trial Type: Multi-site, staircase stepped-wedge randomized controlled trial (RCT) * Duration: 24 months total, with 9-month intervention periods for each group * Participants: 500 participants (Texas n=150 and NYC n=350); Participants are recruited from community-based organizations and through network-based referrals

Randomization:

* 48 networks will be randomized into 8 sequences. * Each network will experience a 3-month control period, followed by either the C4 intervention or the C4 + 3MV intervention.

Interventions:

* C4 Intervention: Focuses on care coordination, addressing participants' needs related to healthcare access, stigma, and mental health services. Uses individualized care plans and support systems to facilitate adherence. * C4 + 3MV Intervention: Incorporates both care coordination and the 3MV (Many Men, Many Voices) behavioral change program. 3MV focuses on reducing stigma, promoting safe behaviors, and improving self-efficacy through group sessions.

Primary and Secondary Outcomes:

* Primary Outcome: PrEP adherence, measured through dried blood spot (DBS) assays to assess drug levels over time. * Secondary Outcomes: Changes in HIV-related health-seeking behavior (e.g., frequency of HIV testing); Autonomy and social support, measured through validated scales; Reduction in stigma and mental health improvements

Data Collection and Monitoring:

* Data will be collected at multiple points using questionnaires, DBS tests, and counseling session evaluations. * A Learn-as-You-Go (LAGO) adaptive analysis will be conducted every 6 months to optimize intervention delivery.

Вмешательства

  • Поведенческое C4 Program
    The C4 intervention is a behavioral program designed to provide care coordination to address structural barriers to PrEP adherence among Black men who have sex with men (MSM). It includes personalized support services, focusing on healthcare access, mental health, and stigma reduction to promote consistent PrEP use. Participants will receive counseling sessions and follow-ups based on their individual needs.
  • Поведенческое C4 + 3MV Program
    This intervention combines the C4 care coordination with the 3MV behavioral program. The 3MV program focuses on behavior change, addressing self-efficacy, stigma, and promoting healthy practices. Through this combination, participants receive both structural and behavioral support to maximize their adherence to PrEP.

Первичные конечные точки

  • PrEP adherence- self report [Срок оценки: 0, 3, 6, 9, 12 months]
  • PrEP adherence- biomarker validation [Срок оценки: 0, 6, and 12 months]
Вторичные конечные точки (1)
  • HIV Testing Frequency [Срок оценки: Every 3 months for 12 months]

Критерии участия

Критерии включения

  • Self-identify as male.
  • Self-Identify as Black people.
  • Aged 18 or older.
  • Self Report having sex with men in the past 6 months.
  • Eligible for PrEP or currently prescribed PrEP.
  • Willing to participate in behavioral intervention sessions.

Критерии исключения

  • Currently diagnosed with HIV.
  • Unable to provide informed consent.
  • Unable to fully engage with the intervention due to health issues.
  • Participating in another clinical trial with conflicting outcomes.

Критерии приведены из реестра в оригинале (на английском). Окончательную оценку соответствия проводит исследовательский центр.

Здоровые добровольцы: Да

Дизайн исследования

Распределение
Рандомизированное
Модель
Последовательный дизайн
Маскирование
Открытое
Основная цель
Профилактика

Центры проведения

США · 2 центра
  • Bronx Health Center — New York
  • Abounding Prosperity, Inc. — Dallas

Идентификаторы

NCT: NCT06661343 · 2000037790 · 1R01MH138225-01

Первоисточники (государственные реестры)

Открыть это исследование на ClinicalTrials.gov ↗